Jubilant Ingrevia Ltd. · NSE:JUBLINGREA

Jubilant Ingrevia — Edelweiss India Conference 2022, Singapore

57 slides from Jubilant Ingrevia's conference presentation, Aug 16, 2022

  1. Slide 1: Intimation of Investor/Analyst Meetings cover letter

    August 16, 2022 BSE Limited National Stock Exchange of India Limited Floor 25, P. J. Towers Exchange Plaza Dalal Street, Fort Bandra Kurla Complex Mumbai - 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 543271 Trading Symbol: JUBLINGREA Subject: Intimation of Investor/ Analyst Meetings Dear Sirs,

  2. Slide 2: Investor Presentation August 2022

    Investor Presentation August 2022

  3. Slide 3: Disclaimer

    Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f

  4. Slide 4: Company Overview

    Company Overview

  5. Slide 5: Jubilant Bhartia Group - Snapshot

    Jubilant Bhartia Group - Snapshot Jubilant Bhartia Group founded by Shyam S Bhartia and Hari S Bhartia, leading industrialists from India Strong presence in diverse sectors like Pharmaceuticals, CDMO (Contract Research & Development Services) and Therapeutics, Specialty Chemicals, Nutraceutical Prod

  6. Slide 6: Integrated Business Model

    Integrated Business Model Jubilant Ingrevia Integrated Operations… 52% of our Pyridine & Picolines Speciality Nutrition & Health Chemical volume is used in-house for value- Chemicals Solutions Intermediates# added products in Speciality Nutrition & Pyridine & Chemicals & for Vitamin B3 Nutrition & H

  7. Slide 7: Glorious Four Decades of Growth

    Glorious Four Decades of Growth Commissioning of Our Journey 10+ years experience in 2019: Started new Acetic Anhydride plant, Bharuch SEZ, GJ (50 KTA) Phase1: Diketene 2018: Started Agro Intermediate plant (800 TPA), Bharuch SEZ Derivative Plant Vitamin B3 2017: Certified for Responsible Care (RC)

  8. Slide 8: Company Snapshot

    Company Snapshot Leadership Revenue Segmentation: By Region (FY’22) Total 1500+ customers - Globally # 1 in 17 Pyridine Derivatives • Speciality Chemicals: 470 - Globally among Top 2 in (Pyridine + Beta) N.America • Nutrition & Health Solutions: 460 RoW Domestic Sales 5% 10% for International • Chem

  9. Slide 9: Executive Leadership Team

    Executive Leadership Team Rajesh Srivastava Chief Executive Officer & Managing Director 35 years of industry experience Anil Khubchandani Chandan Singh Sumit Das Ashish Kumar Sinha Co-CEO & WTD Co-CEO SVP – Nutrition & VP – Animal & Human Speciality Chemicals Chemical Intermediates Health Ingredient

  10. Slide 10: Multi Location Manufacturing & Operation Excellence

    Multi Location Manufacturing & Operation Excellence Manufacturing Facilities 463 acres 310 acres 144 acres 109 acres 3.5 acres Gajraula, Uttar Pradesh, Bharuch, Gujarat, India Nira, Maharashtra, India Samlaya, Gujarat, India Ambernath, Maharashtra, India Speciality Chemicals, Chemical Intermediates

  11. Slide 11: Research Development & Technology (RDT)

    Research Development & Technology (RDT) 3 RDT centers in Noida, Gajraula and Bharuch 35 Key technology platforms developed & commercialized to global standards. Some are unique: Ammoxidation, Key Grignard etc. Highlights 92 highly qualified scientists (22 PhDs) 60+ Products in Pipeline for next 4 ye

  12. Slide 12: End Usage Applications for Pharma, Agrochemicals & Nutraceuticals

    End Usage Applications for Pharma, Agrochemicals & Nutraceuticals Therapeutic Category Our Product Category (GMP & Non-GMP) (Used in ~ 53 APIs) Pyridine, Picolines Amino Methyl Chloro/ Bromo/ Pyridines Fluoro Pyridines Antipyretic Analgesic Antifibrosis Off- Patented Amino Pyridines Hydroxy Methyl P

  13. Slide 13: Financial Highlights: Q1 FY'23

    Financial Highlights: Q1 FY’23

  14. Slide 14: Chairmen's Message on Q1'FY23 Financial Results

    Chairmen’s Message on Q1’FY23 Financial Results Mr. Shyam S Bhartia Mr. Hari S Bhartia Chairman Co-Chairman “We are glad to announce steady operational and financial performance in Q1’FY23, in the backdrop of inflationary headwinds leading to higher raw material and energy costs during the quarter.

  15. Slide 15: Financial Highlights: Key Financial Parameters (USD Million)

    Financial Highlights1 : Key Financial Parameters (USD Million) Highlights USD 641 Mn. USD 112 Mn. 17.4% USD 62 Mn. 9.6% USD 0.39 FY22 Sales EBITDA EBITDA (%) PAT PAT (%) EPS 42% YoY 38% YoY (50) bps 51% YoY 58 bps 51% YoY Highlights USD 452 Mn. USD 81 Mn. 17.9% USD 41 Mn. 9.1% USD 0.26 FY21 2 Sales

  16. Slide 16: Financial Highlights: Key Financial Parameters (Rs Crore)

    Financial Highlights1 : Key Financial Parameters (Rs Crore) Highlights ₹ 4,949 Cr. ₹ 863 Cr. 17.4% ₹ 477 Cr. 9.6% ₹ 30.0 FY22 Sales EBITDA EBITDA (%) PAT PAT (%) EPS 42% YoY 38% YoY (50) bps 51% YoY 58 bps 51% YoY Highlights ₹ 3,491 Cr. ₹ 627 Cr. 17.9% ₹ 316 Cr. 9.1% ₹ 19.9 FY21 2 Sales EBITDA EBITD

  17. Slide 17: Q1 FY'23 Financial Results Summary (USD Million)

    Jubilant Ingrevia – Q1 FY’23 Financial Results Summary (USD Million) Particulars1 Q1'FY22 Q1'FY23 YoY (%) FINANCIAL HIGHLIGHTS Revenue Speciality Chemicals 39.5 49.6 26% • Overall Revenue grew by 2% on YoY basis, mainly due to higher sales Nutrition & Health Solutions 21.6 19.5 (10%) performance by

  18. Slide 18: Q1 FY'23 Financial Results Summary (Rs Crore)

    Jubilant Ingrevia – Q1 FY’23 Financial Results Summary (Rs Crore) Particulars1 Q1'FY22 Q1'FY23 YoY (%) FINANCIAL HIGHLIGHTS Revenue Speciality Chemicals 305 382 26% • Overall Revenue grew by 2% on YoY basis, mainly due to higher sales Nutrition & Health Solutions 167 150 (10%) performance by Special

  19. Slide 19: FY'22 Financial Results Summary (USD Million)

    Jubilant Ingrevia – FY’22 Financial Results Summary (USD Million) Particulars1 FY212 FY22 YoY (%) FINANCIAL HIGHLIGHTS Revenue Speciality Chemicals 145.6 180.4 24% • Revenue grew by 42% on YoY basis, driven by growth across Business Nutrition & Health Solutions 81.6 99.4 22% segments. Chemical Inter

  20. Slide 20: FY'22 Financial Results Summary (Rs Crore)

    Jubilant Ingrevia – FY’22 Financial Results Summary (Rs Crore) Particulars1 FY212 FY22 YoY (%) FINANCIAL HIGHLIGHTS Revenue Speciality Chemicals 1,124 1,393 24% • Revenue grew by 42% on YoY basis, driven by growth across Business Nutrition & Health Solutions 630 767 22% segments. Chemical Intermedia

  21. Slide 21: Debt Profile – As on 30th June, 2022 (USD Million)

    Debt Profile – As on 30th June, 2022 (USD Million) Particulars1 30-Jun-21 31-Mar-22 30-Jun-22 Long Term Borrowings 29.4 13.0 - Short Term Borrowings 29.8 16.7 36.9 Total Gross Debt 59.2 29.7 36.9 Cash & Equivalent 9.1 6.3 7.4 Total Net Debt 50.1 23.4 29.6 YoY change -58% -41%  We have successfully

  22. Slide 22: Debt Profile – As on 30th June, 2022 (Rs Crore)

    Debt Profile – As on 30th June, 2022 (Rs Crore) Particulars1 30-Jun-21 31-Mar-22 30-Jun-22 Long Term Borrowings 227 100 - Short Term Borrowings 230 129 285 Total Gross Debt 457 229 285 Cash & Equivalent 70 49 57 Total Net Debt 386 181 228 YoY change -58% -41%  We have successfully reduced our high

  23. Slide 23: Balance Sheet – Key Parameters/Ratios (Pro-Forma)

    Balance Sheet – Key Parameters/Ratios (Pro-Forma2) Return On Capital Employed (RoCE) ## Return on Equity ## 27.8% 21.9% (%age) 20.2% 20.8% (%age) 16.4% 15.7% FY'21 FY'22 Q1'FY23 FY'21 FY22 Q1'FY23 Asset / Turnover and Return On Asset (RoA) Net Working Capital 15.0% 16.2% # 17.9% 2.0x 2.8x 2.8x 55 Da

  24. Slide 24: Business Segments Overview

    BUSINESS SEGMENTS OVERVIEW

  25. Slide 25: Speciality Chemicals – Segment Snapshot

    Speciality Chemicals – Segment Snapshot Geographical Revenue Split (FY’22) 70+ Products (Pyridines & Picolines, Globally among Top 2 in Globally lowest cost Domestic Sales for International Cyanopyridines, (Pyridine+Beta); producer of Pyridine Piperidines, Consumption Globally #1 in 17 Pyridine offe

  26. Slide 26: Speciality Chemicals Segment Highlights – Q1 FY'23 (USD Million)

    Speciality Chemicals Segment Highlights – Q1 FY’23 (USD Million) FINANCIAL HIGHLIGHTS Particulars1 Q1'FY22 Q1'FY23 YoY (%) Revenue 39.5 49.6 26%  Specialty Chemicals revenue grew by 26% on YoY basis driven by Reported EBITDA 10.9 8.3 (24%) higher volume across product segments Reported EBITDA Margi

  27. Slide 27: Speciality Chemicals Segment Highlights – Q1 FY'23 (Rs Crore)

    Speciality Chemicals Segment Highlights – Q1 FY’23 (Rs Crore) FINANCIAL HIGHLIGHTS Particulars1 Q1'FY22 Q1'FY23 YoY (%) Revenue 305 382 26%  Specialty Chemicals revenue grew by 26% on YoY basis driven by Reported EBITDA 84 64 (24%) higher volume across product segments Reported EBITDA Margin (%) 27

  28. Slide 28: Speciality Chemicals Segment Highlights – FY'22 (USD Million)

    Speciality Chemicals Segment Highlights – FY’22 (USD Million) Particulars1 FY212 FY22 YoY (%) FINANCIAL HIGHLIGHTS Revenue 145.6 180.4 24%  Specialty Chemicals revenue grew by 24% on YoY Reported EBITDA 34.8 40.5 16% basis driven by higher volume across products and Reported EBITDA Margin (%) 23.9%

  29. Slide 29: Speciality Chemicals Segment Highlights – FY'22 (Rs Crore)

    Speciality Chemicals Segment Highlights – FY’22 (Rs Crore) Particulars1 FY212 FY22 YoY (%) FINANCIAL HIGHLIGHTS Revenue 1,124 1,393 24%  Specialty Chemicals revenue grew by 24% on YoY Reported EBITDA 268 312 16% basis driven by higher volume across products and Reported EBITDA Margin (%) 23.9% 22.4

  30. Slide 30: Nutrition & Health Solutions – Segment Snapshot

    Nutrition & Health Solutions – Segment Snapshot Global top 2 in Vitamin B3 Revenue Segmentation (FY’22) 5 Nutrition Ingredients & Domestic leader in Vitamin 100% in-house sourcing Domestic Sales for By End use B4 (Feed); Entered into of Beta Picoline (Key RM) for By Region Domestic Consumption Cosme

  31. Slide 31: Nutrition & Health Solutions Segment Highlights – Q1 FY'23 (USD Million)

    Nutrition & Health Solutions Segment Highlights – Q1 FY’23 (USD Million) Particulars1 Q1'FY22 Q1'FY23 YoY (%) FINANCIAL HIGHLIGHTS Revenue 21.6 19.5 (10%)  Nutritional Business sales was impacted mainly due to spread of Bird Reported EBITDA 3.4 2.4 (29%) Flu and Swine Flu in Europe US region, coupl

  32. Slide 32: Nutrition & Health Solutions Segment Highlights – Q1 FY'23 (Rs Crore)

    Nutrition & Health Solutions Segment Highlights – Q1 FY’23 (Rs Crore) FINANCIAL HIGHLIGHTS Particulars1 Q1'FY22 Q1'FY23 YoY (%) Revenue 167 150 (10%)  Nutritional Business sales was impacted mainly due to spread of Bird Reported EBITDA 27 19 (29%) Flu and Swine Flu in Europe US region, coupled with

  33. Slide 33: Nutrition & Health Solutions Segment Highlights – FY'22 (USD Million)

    Nutrition & Health Solutions Segment Highlights – FY’22 (USD Million) Particulars1 FY212 FY22 YoY (%) FINANCIAL HIGHLIGHTS Revenue 81.6 99.4 22% Reported EBITDA 16.9 21.3 26%  Nutrition and Health Solutions revenue grew by 22% Reported EBITDA Margin (%) 20.7% 21.4% - on YoY basis. • Growth of Vitam

  34. Slide 34: Nutrition & Health Solutions Segment Highlights – FY'22 (Rs Crore)

    Nutrition & Health Solutions Segment Highlights – FY’22 (Rs Crore) Particulars1 FY212 FY22 YoY (%) FINANCIAL HIGHLIGHTS Revenue 630 767 22% Reported EBITDA 130 164 26%  Nutrition and Health Solutions revenue grew by 22% Reported EBITDA Margin (%) 20.7% 21.4% - on YoY basis. • Growth of Vitamin Busi

  35. Slide 35: Chemical Intermediates – Segment Snapshot

    Chemical Intermediates – Segment Snapshot Entered Value added Region wise Revenue Segmentation Acetic Anhydride: 9 Products Globally No. 2 in derivative Propionic For Segment (FY’22) (Acetic Anhydride, Ethyl Domestic Sales for Merchant Mkt Anhydride to RoW 3% Acetate ,Propionic Anhydride, Internatio

  36. Slide 36: Chemical Intermediates Segment Highlights – Q1 FY'23 (USD Million)

    Chemical Intermediates Segment Highlights – Q1 FY’23 (USD Million) Particulars1 Q1'FY22 Q1'FY23 YoY (%) FINANCIAL HIGHLIGHTS Revenue 87.2 82.0 (6%)  Chemical Intermediates business continue to witness strong Reported EBITDA 23.8 9.9 (58%) demand resulting into robust volume growth. Reported EBITDA

  37. Slide 37: Chemical Intermediates Segment Highlights – Q1 FY'23 (Rs Crore)

    Chemical Intermediates Segment Highlights – Q1 FY’23 (Rs Crore) Particulars1 Q1'FY22 Q1'FY23 YoY (%) FINANCIAL HIGHLIGHTS Revenue 673 633 (6%)  Chemical Intermediates business continue to witness strong Reported EBITDA 184 76 (58%) demand resulting into robust volume growth. Reported EBITDA Margin

  38. Slide 38: Chemical Intermediates Segment Highlights – FY'22 (USD Million)

    Chemical Intermediates Segment Highlights – FY’22 (USD Million) Particulars1 FY212 FY22 YoY (%) FINANCIAL HIGHLIGHTS Revenue 225.1 361.4 61% Reported EBITDA 30.6 54.0 77%  Chemical Intermediates revenue grew by 61% on YoY Reported EBITDA Margin (%) 13.6% 14.9% basis • Chemical Intermediates revenue

  39. Slide 39: Chemical Intermediates Segment Highlights – FY'22 (Rs Crore)

    Chemical Intermediates Segment Highlights – FY’22(Rs Crore) Particulars1 FY212 FY22 YoY (%) FINANCIAL HIGHLIGHTS Revenue 1,738 2,789 61%  Chemical Intermediates revenue grew by 61% on YoY Reported EBITDA 236 417 77% basis Reported EBITDA Margin (%) 13.6% 14.9% • Chemical Intermediates revenue growt

  40. Slide 40: Outlook & Growth Plans

    Outlook & Growth Plans

  41. Slide 41: Outlook | As on 30th June, 2022

    Outlook | As on 30th June, 2022  We expect overall healthy revenue growth during FY’23, led by volume growth in Specialty Chemicals & Chemical intermediate business segment. Commissioning of our three new capex of CDMO GMP, CDMO non-GMP and Acetic Anhydride is likely to aid the revenue growth.  In

  42. Slide 42: Growth Capex Investment Plan – Business Wise (USD Million)

    Growth Capex Investment Plan – Business Wise (USD Million) (Already Committed & to be Committed) Additional Capex to be Committed during FY’23 & FY’24~ USD 149.0 Million Estimated Cash Outflow Committed till date ~ USD 116.6 Million ~ (USD 61.3 Mn, USD 84.2 Mn. & USD 77.7 Mn. respectively in FY’23 –

  43. Slide 43: Growth Capex Investment Plan – Business Wise (Rs Crore)

    Growth Capex Investment Plan – Business Wise (Rs Crore) (Already Committed & to be Committed) Additional Capex to be Committed during FY’23 & FY’24~ Rs. 1150 Crores Committed till date ~ Rs. 900 Crores Estimated Cash Outflow (From FY’22 to Q1’FY23, Total Cash Outflow ~ Rs.312 Cr.) ~ (Rs.473 Cr, Rs.6

  44. Slide 44: Capacity Build-Up Plan – FY'22 to FY'25

    Capacity Build- Up Plan – FY’22 to FY’25 (over Base of FY’22) Overall Capacity Build-Up Speciality Chemicals Capacity Build-Up Capacity Expansion Plan Capacity Expansion Plan (Overall capacity increase : 40.5% & CAGR: 12.0%) (Overall capacity increase: 44.7% & CAGR: 13.1%) 30.0% 32.3% 15.6% 1.5% 7.9

  45. Slide 45: Structural Shift towards Speciality via Growth Capex Plans (USD Million)

    Structural Shift towards Speciality via Growth Capex Plans (USD Million) Speciality & Nutrition will be 65% of Revenue up from present 46% post commissioning of our announced growth capex plans Revenue in INR Crores at Base price of FY’21 Speciality, Nutrition & Others: 65% Acetyls: 35% Speciality,

  46. Slide 46: Structural Shift towards Speciality via Growth Capex Plans (Rs Crore)

    Structural Shift towards Speciality via Growth Capex Plans (Rs Crore) Speciality & Nutrition will be 65% of Revenue up from present 46% post commissioning of our announced growth capex plans Revenue in INR Crores at Base price of FY’21 Speciality, Nutrition & Others: 65% Acetyls: 35% Speciality, Nut

  47. Slide 47: Quality, Business Excellence, Sustainability

    BUSINESS QUALITY SUSTAINABILITY EXCELLENCE

  48. Slide 48: Jubilant Ingrevia: Global Accreditation

    Jubilant Ingrevia: Global Accreditation Select Certifications Gajraula Bharuch Nira Samlaya Ambernath Responsible Care    RC 14001:2015 ISO      9001:2015 ISO    22000:2005 ISO     14001:2015 ISO     45001:2018 FSSAI     FAMI-QS   HALAL    KOSHER   GMP State State FDA G

  49. Slide 49: Business Excellence and Digital Transformation

    Business Excellence and Digital Transformation Belt Competencies (FY’22) Digital Transformation Black Belts: 07 Green Belts: 103 Yellow Belts: 95  Our journey started in 2018 with an objective to improve Business Excellence  Operational efficiency Tools & Processes  Business & Supply chain proces

  50. Slide 50: Bring Progressive Social Change via Strategic Multi-Stakeholder Partnership

    Bring Progressive Social Change via Strategic Multi-Stakeholder Partnership Mission: To develop multi-stakeholder sustainable Aspiring to touch 1 Million Established models to bring about ‘social change’ involving the Lives through in 2007 knowledge generation & sharing, experiential lives social in

  51. Slide 51: Sustainability Journey

    Sustainability Journey 2001 2002 2003 2005 2008 2009 2010 2013 2015 2019 2021 Climate Became GRI Change Became UNGC SoFI Sustainability Sustainability Sustainability Jubilant Bhartia 1st EvoVadis Dow Jones ISO ISO 14000 14000 Sustainability Organization Mitigation Signatory and Sustainability Goals

  52. Slide 52: Our Vision, Values, Promise and Philosophy

    Our Vision, Values, Promise and Philosophy OUR PHILOSOPHY Caring Sharing Growing

  53. Slide 53: For More Information

    For More Information For Investors: Surajit Pal Ph: +91 120 436 1002 E-mail: Surajit.pal1@jubl.com Pavleen Taneja Ph: +91 120 436 1021 E-mail: pavleen.taneja@jubl.com Jubilant Ingrevia Limited Thank you for your time 1A, Sector-16A, Noida - 201 301, Uttar Pradesh, India Email: support@jubl.com | www

  54. Slide 54: Appendix I: Income Statement – Q1'FY23 (USD Million)

    Appendix I: Income Statement – Q1’FY23 (USD Million) Particulars1 Q1'FY22 Q1'FY23 YoY (%) Total Revenue from Operations 148.3 151.1 2% Speciality Chemicals 39.5 49.6 26% Nutrition & Health Solutions 21.6 19.5 (10%) Chemical Intermediates 87.2 82.0 (6%) Total Expenditure 111.8 132.8 19% Other Income

  55. Slide 55: Appendix II: Income Statement – Q1'FY23 (Rs Crore)

    Appendix II: Income Statement – Q1’FY23 (Rs Crore) Particulars1 Q1'FY22 Q1'FY23 YoY (%) Total Revenue from Operations 1,145 1,166 2% Speciality Chemicals 305 382 26% Nutrition & Health Solutions 167 150 (10%) Chemical Intermediates 673 633 (6%) Total Expenditure 863 1,025 19% Other Income 6 10 69% S

  56. Slide 56: Appendix III: Income Statement – FY'22 (USD Million)

    Appendix III: Income Statement – FY’22 (USD Million) Particulars1 FY212 FY22 YoY (%) Total Revenue from Operations 452.3 641.3 42% Speciality Chemicals 145.6 180.4 24% Nutrition & Health Solutions 81.6 99.4 22% Chemical Intermediates 225.1 361.4 61% Total Expenditure 398.4 533.5 34% Other Income 1.9

  57. Slide 57: Appendix IV: Income Statement – FY'22 (Rs Crore)

    Appendix IV: Income Statement – FY’22 (Rs Crore) Particulars1 FY212 FY22 YoY (%) Total Revenue from Operations 3,491 4,949 42% Speciality Chemicals 1,124 1,393 24% Nutrition & Health Solutions 630 767 22% Chemical Intermediates 1,738 2,789 61% Total Expenditure 3,075 4,118 34% Other Income 15 31 Seg

Jubilant Ingrevia — Edelweiss India Conference 2022, Singapore on 6ix